推进帕金森病的精准医学治疗方法,利用共享的定量系统药理学模型和框架
Christopher Denaro1, Diane Stephenson2, Martijn L T M Müller2
1Center for Computational and Integrative Biology, Rutgers University, Camden, NJ, United States.
Frontiers in systems biology
|August 14, 2025
概括
针对帕金森病 (PD) 病理生理学的精准医学策略显示出希望. 量化系统药理 (QSP) 建模可以加速开发急需的PD疾病修饰疗法.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 遗传学 是一个遗传学.
背景情况:
- 帕金森病 (PD) 的治疗方法越来越多地针对潜在的病理生理学.
- 基因发现正在推动PD的精准医学方法.
- SNCA,LRRK2和GBA是PD正在研究的关键基因.
研究的目的:
- 审查开发帕金森病疾病修饰疗法的进展和挑战.
- 突出定量系统药理 (QSP) 建模在加速PD药物开发中的潜力.
主要方法:
- 对PD中的遗传发现和机制模型的审查.
- 分析当前的治疗策略和临床试验结果.
- 探索监管框架和建模方法,如基于模型的药物开发 (MIDD).
主要成果:
- 虽然没有批准基因向的PD疗法,但已经吸取了宝贵的经验教训.
- 常见的路径,如 lysosomal 功能,炎症和线粒体功能都涉及到.
- 需要生物标志物来证明目标参与和机制证明.
结论:
- 定量系统药理 (QSP) 建模可以显著促进PD疗法的发展.
- 数据,监管框架和分阶段系统的融合可以加速进步.
- 合作方法对于开发急需的帕金森病修饰疾病治疗方法至关重要.
更多相关视频
相关概念视频
Parkinson's Disease: Treatment
380
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
380
Pharmacokinetic Models: Overview
1.1K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
1.1K
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
126
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
126
Pharmacokinetic Models: Comparison and Selection Criterion
149
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
149
Parkinson's Disease: Overview
704
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
704
Analysis of Population Pharmacokinetic Data
383
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
383


